Children who are exposed to metformin in the womb may later have a higher risk of obesity, finds a new study.
Pregnant mothers suffering from polycystic ovary syndrome (PCOS) take metformin, which results in fewer miscarriages and premature births. However, a new study has shown that children have a higher risk of obesity in later life who are exposed to metformin in the womb.// "We can't rule out that these children may have more health problems as adults," says PhD candidate Liv Guro Engen Hanem at NTNU's Department of Clinical and Molecular Medicine.
‘Metformin might benefit pregnant mothers with PCOS; however, they pose obesity risk to offspring that might lead to obesity-related ailments.’
Hanem is the first author of an article published in the The Lancet Child & Adolescence Health journal. The results are contrary to the researchers' original hypothesis. They assumed that the children would have a lower risk of obesity later, due to better growth conditions in utero.
Millions of pregnant women use metformin, partly due to PCOS but most often to treat gestational diabetes. Few negative side effects have been demonstrated from its use, and none for the fetus. But so far we know little about possible long-term effects.
The results show that 8-year-old children who were exposed to metformin in utero (in the womb) on average had a higher body mass index (BMI) and waist circumference compared to children of women in a control group. This control group was given an inactive placebo instead.
A higher BMI can lead to negative effects for children later in life from obesity-related ailments.
Advertisement
These children, when measured as 8-year-olds, however, did have a larger waist circumference as compared to children with mothers who did not have PCOS. Larger waist circumference is associated with an unfavorable distribution of body fat.
Advertisement
The research group examined 257 pregnant women (274 pregnancies) with PCOS during the period 2005 to 2009. The women received metformin or a placebo during pregnancy.
Researchers conducted follow-up measurements of height, weight, BMI and abdominal circumference on 141 of these children when they were 5 to 10 years old.
Metformin-exposed children were compared with placebo-exposed children. The researchers compared the placebo-exposed children (of mothers with PCOS) with children from a Norwegian reference population.
Source-Eurekalert